CDx Precision Health
Research - Palo Alto, California, United States
CDx Precision Health Employees
CDx Precision Health Details
Leveling the financial playing field for CDx companies and enabling them to strike more lucrative deals through strengthened, data-driven negotiating positions. By characterizing the pharmacoeconomics of precision (or personalized) healthcare using biomarker-enabled companion diagnostics (CDx) as Real Options within a decision-tree analysis framework, CDx Precision Health is determining the financial value added by the CDx molecular test within the stratified medicine ecosystem. For the representative oncological cases investigated, the risk-adjusted expected Net Present Value (eNPV) of the CDx Precision Health's financial model predictions is in excess of $250 Million. The results of these economic studies are being used by the key precision medicine stakeholders, including diagnostic biotool testing & targeted treatment healthcare-providers and payers.
CDx Precision Health Technologies
Email Providers
Outlook
CMS
WP Engine
Other
Microsoft Office 365
Hosting
Google Cloud Hosting
Online Video Platforms
Vimeo